

Michael D Keller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1592077/publications.pdf>

Version: 2024-02-01

51
papers

2,051
citations

394286

19
h-index

254106

43
g-index

53
all docs

53
docs citations

53
times ranked

3114
citing authors

#	ARTICLE	IF	CITATIONS
1	Practice parameter for the diagnosis and management of primary immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1186-1205.e78.	1.5	564
2	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 520-531.	1.5	278
3	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood</i> , 2018, 132, 1737-1749.	0.6	128
4	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1498-1505.e1.	1.5	117
5	SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. <i>Blood</i> , 2020, 136, 2905-2917.	0.6	108
6	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. <i>Blood</i> , 2020, 135, 2094-2105.	0.6	87
7	Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1192-1197.	1.5	67
8	Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 544-550.e4.	1.5	54
9	Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 46-69.	1.5	54
10	Virus-specific T-cell therapies for patients with primary immune deficiency. <i>Blood</i> , 2020, 135, 620-628.	0.6	45
11	Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1146-1153.	2.0	45
12	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.	2.0	36
13	Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. <i>Cytotherapy</i> , 2016, 18, 1515-1524.	0.3	33
14	T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. <i>British Journal of Haematology</i> , 2019, 187, 206-218.	1.2	29
15	Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells. <i>Molecular Therapy</i> , 2015, 23, 179-183.	3.7	28
16	Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. <i>Frontiers in Immunology</i> , 2018, 9, 556.	2.2	27
17	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. <i>Blood Advances</i> , 2019, 3, 2057-2068.	2.5	27
18	Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. <i>Blood Advances</i> , 2021, 5, 3309-3321.	2.5	26

#	ARTICLE	IF	CITATIONS
19	Future of Care for Patients With Chronic Granulomatous Disease: Gene Therapy and Targeted Molecular Medicine. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, S40-S44.	0.6	22
20	Molecular diagnosis of childhood immune dysregulation, polyendocrinopathy, and enteropathy, and implications for clinical management. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 327-339.	1.5	22
21	Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. <i>Blood Advances</i> , 2022, 6, 2520-2534.	2.5	19
22	Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 809-818.	2.0	16
23	<i>χ</i> Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	16
24	Immunizing the imperfect immune system. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 562-571.e1.	0.5	16
25	Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients. <i>Cytotherapy</i> , 2018, 20, 385-393.	0.3	15
26	Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 578-588.	1.9	15
27	SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793197.	2.2	14
28	Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. <i>Blood Advances</i> , 2022, 6, 2897-2907.	2.5	13
29	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. <i>Blood</i> , 2022, 140, 208-221.	0.6	13
30	Major Histocompatibility Complex Class II Deficiency due to a Novel Mutation in RFXANK in a Child of Mexican Descent. <i>Journal of Clinical Immunology</i> , 2016, 36, 4-5.	2.0	11
31	Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders. <i>Current Allergy and Asthma Reports</i> , 2017, 17, 3.	2.4	10
32	Generation of Zika virus-specific T cells from seropositive and virus-naïve donors for potential use as an autologous or "off-the-shelf" immunotherapeutic. <i>Cytotherapy</i> , 2019, 21, 840-855.	0.3	10
33	POLD1 Deficiency Reveals a Role for POLD1 in DNA Repair and T and B Cell Development. <i>Journal of Clinical Immunology</i> , 2021, 41, 270-273.	2.0	10
34	Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. <i>Cytotherapy</i> , 2021, 23, 65-76.	0.3	10
35	Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 298.	1.8	8
36	The pipeline of antiviral T cell therapy: what's in the clinic and undergoing development. <i>Transfusion</i> , 2020, 60, 7-10.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies. <i>Cytotherapy</i> , 2021, 23, 694-703.	0.3	7
38	Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1944-1946.	2.0	6
39	Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains. <i>Cytotherapy</i> , 2022, 24, 10-15.	0.3	6
40	Case Report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient. <i>F1000Research</i> , 2019, 8, 2.	0.8	5
41	Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders. <i>Frontiers in Immunology</i> , 2019, 10, 621.	2.2	4
42	EBV-directed viral-specific T-cell lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28126.	0.8	4
43	T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1. <i>Frontiers in Immunology</i> , 2020, 11, 575977.	2.2	4
44	Evaluation and Treatment of Febrile Ulceronecrotic Mucha-Habermann Disease With Ruxolitinib and Tocilizumab as Guided by Cytokine Profile. <i>JAMA Dermatology</i> , 2021, 157, 1381-1383.	2.0	4
45	Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 439-447.	1.8	4
46	Case Report: Unmanipulated Matched Sibling Donor Hematopoietic Cell Transplantation In TBX1 Congenital Athymia: A Lifesaving Therapeutic Approach When Facing a Systemic Viral Infection. <i>Frontiers in Immunology</i> , 2021, 12, 721917.	2.2	2
47	Improving transplantation for IL2RG/JAK3 SCID. <i>Blood</i> , 2017, 129, 2049-2050.	0.6	1
48	Recurrent lymphadenitis in a female XIAP/BIRC4 mutation carrier with normal lyonization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1002-1005.e2.	2.0	1
49	Flow-based analysis of cell division identifies highly active populations within plasma products during mixed lymphocyte cultures. <i>Blood Transfusion</i> , 2021, 19, 456-466.	0.3	1
50	Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel. <i>Pediatric Hematology and Oncology</i> , 2022, , 1-9.	0.3	0
51	Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data from the USIDNET Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	2.0	0